Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AYTUNASDAQ:BCTXNASDAQ:LIPONYSE:OGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYTUAytu BioPharma$1.95$1.49$0.95▼$2.99$12.03M0.05367,015 shs94,423 shsBCTXBriaCell Therapeutics$3.12-11.6%$3.78$2.81▼$29.40$11.57M1.3552,164 shs124,884 shsLIPOLipella Pharmaceuticals$2.56-5.6%$2.61$1.97▼$12.00$11.43M0.44725,797 shs21,329 shsOGENOragenics$4.36-5.8%$5.27$3.12▼$75.60$3.12M0.94105,666 shs80,798 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYTUAytu BioPharma0.00%-2.50%-24.71%+61.84%-34.34%BCTXBriaCell Therapeutics0.00%-9.30%+6.85%-18.75%-84.12%LIPOLipella Pharmaceuticals0.00%-14.41%+14.75%+19.02%-50.79%OGENOragenics0.00%+1.87%-25.32%-48.10%-91.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAYTUAytu BioPharma1.4742 of 5 stars0.04.00.03.43.10.00.6BCTXBriaCell Therapeutics1.6887 of 5 stars3.52.00.00.01.80.00.6LIPOLipella Pharmaceuticals2.2429 of 5 stars0.05.00.00.02.73.30.6OGENOragenics0.4302 of 5 stars0.04.00.00.02.40.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAYTUAytu BioPharma 0.00N/AN/AN/ABCTXBriaCell Therapeutics 3.00Buy$32.00925.64% UpsideLIPOLipella Pharmaceuticals 0.00N/AN/AN/AOGENOragenics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OGEN, LIPO, BCTX, and AYTU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2025BCTXBriaCell TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYTUAytu BioPharma$81.66M0.15N/AN/A$4.64 per share0.42BCTXBriaCell TherapeuticsN/AN/AN/AN/A($2.20) per shareN/ALIPOLipella Pharmaceuticals$536.36K21.31N/AN/A$4.33 per share0.59OGENOragenics$40K77.94N/AN/A$0.61 per share7.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYTUAytu BioPharma-$15.84M-$0.72N/A∞N/A-7.62%-19.30%-4.80%N/ABCTXBriaCell Therapeutics-$4.79M-$5.03N/AN/AN/AN/AN/A-191.19%N/ALIPOLipella Pharmaceuticals-$4.62M-$4.08N/A∞N/A-882.82%-192.33%-154.24%N/AOGENOragenics-$20.66M-$33.63N/A∞N/AN/A-2,087.95%-486.56%N/ALatest OGEN, LIPO, BCTX, and AYTU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q3 2025AYTUAytu BioPharma-$0.17$0.20+$0.37$0.21$13.74 million$18.45 million5/14/2025Q1 2025LIPOLipella PharmaceuticalsN/A-$0.64N/A-$0.64N/A$0.13 million3/27/2025Q4 2024LIPOLipella Pharmaceuticals-$2.43-$1.19+$1.24-$1.19N/A$0.17 million3/17/2025Q2 2025BCTXBriaCell Therapeutics-$1.94-$2.33-$0.39-$2.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAYTUAytu BioPharmaN/AN/AN/AN/AN/ABCTXBriaCell TherapeuticsN/AN/AN/AN/AN/ALIPOLipella PharmaceuticalsN/AN/AN/AN/AN/AOGENOragenicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYTUAytu BioPharma0.320.980.81BCTXBriaCell TherapeuticsN/A1.651.65LIPOLipella PharmaceuticalsN/A2.972.97OGENOragenicsN/A1.931.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYTUAytu BioPharma33.49%BCTXBriaCell Therapeutics15.42%LIPOLipella Pharmaceuticals74.31%OGENOragenics18.71%Insider OwnershipCompanyInsider OwnershipAYTUAytu BioPharma3.60%BCTXBriaCell Therapeutics5.73%LIPOLipella Pharmaceuticals32.11%OGENOragenics4.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAYTUAytu BioPharma1606.17 million6.00 millionNot OptionableBCTXBriaCell Therapeutics83.71 million3.50 millionOptionableLIPOLipella Pharmaceuticals44.47 million821,000Not OptionableOGENOragenics5715,00010.98 millionN/AOGEN, LIPO, BCTX, and AYTU HeadlinesRecent News About These CompaniesOragenics, Inc. to Present ONP-002 at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society SymposiumJune 12 at 12:21 AM | nasdaq.comOragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society SymposiumJune 10, 2025 | finance.yahoo.comOragenics (NYSE:OGEN) Shares Down 4.6% - What's Next?June 6, 2025 | americanbankingnews.comOragenics (NYSE:OGEN) Trading Down 4.6% - Time to Sell?June 6, 2025 | marketbeat.comOragenics Inc.June 4, 2025 | wsj.comOragenics, Inc. Announces One-for-Thirty Reverse Stock SplitMay 29, 2025 | finance.yahoo.comOragenics Hosts Neurotrauma Medicine Webinar PresentationMay 20, 2025 | tipranks.comOragenics gains Australia’s nod for concussion therapy trialMay 15, 2025 | uk.investing.comOragenics, Inc. to Host Webinar on ONP-002 and Addressing Unmet Needs in Concussion TreatmentMay 14, 2025 | nasdaq.comOragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in AustraliaMay 13, 2025 | globenewswire.comOragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion ...May 12, 2025 | gurufocus.comOragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic VisionMay 12, 2025 | globenewswire.comOragenics Appoints Janet Huffman as CEO and CFOMay 2, 2025 | tipranks.comOragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury ConferenceApril 23, 2025 | manilatimes.netOragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference | OGEN ...April 23, 2025 | gurufocus.comOragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion TrialApril 9, 2025 | finance.yahoo.comOragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery SummitApril 7, 2025 | globenewswire.comOragenics provides Q1 shareholder update on strategic financial progressMarch 28, 2025 | markets.businessinsider.comOragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial ProgressMarch 27, 2025 | globenewswire.comOragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-KMarch 18, 2025 | globenewswire.comOragenics submits IB for Phase II clinical trial of ONP-002 in mTBIMarch 6, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsPlug Power: Is Q1 Noise An Opportunity for Accumulation?By Jeffrey Neal Johnson | May 17, 2025View Plug Power: Is Q1 Noise An Opportunity for Accumulation?OGEN, LIPO, BCTX, and AYTU Company DescriptionsAytu BioPharma NASDAQ:AYTU$1.95 0.00 (0.00%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.02 +0.07 (+3.33%) As of 06/13/2025 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.BriaCell Therapeutics NASDAQ:BCTX$3.12 -0.41 (-11.61%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.15 +0.03 (+0.96%) As of 06/13/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Lipella Pharmaceuticals NASDAQ:LIPO$2.56 -0.15 (-5.57%) Closing price 06/13/2025 03:58 PM EasternExtended Trading$2.56 +0.00 (+0.04%) As of 06/13/2025 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.Oragenics NYSE:OGEN$4.36 -0.27 (-5.83%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$4.32 -0.04 (-1.03%) As of 06/13/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
